Patrick M. Forde

18.8k total citations · 6 hit papers
186 papers, 5.7k citations indexed

About

Patrick M. Forde is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Patrick M. Forde has authored 186 papers receiving a total of 5.7k indexed citations (citations by other indexed papers that have themselves been cited), including 132 papers in Oncology, 108 papers in Pulmonary and Respiratory Medicine and 28 papers in Cancer Research. Recurrent topics in Patrick M. Forde's work include Cancer Immunotherapy and Biomarkers (104 papers), Lung Cancer Treatments and Mutations (63 papers) and Lung Cancer Diagnosis and Treatment (32 papers). Patrick M. Forde is often cited by papers focused on Cancer Immunotherapy and Biomarkers (104 papers), Lung Cancer Treatments and Mutations (63 papers) and Lung Cancer Diagnosis and Treatment (32 papers). Patrick M. Forde collaborates with scholars based in United States, Canada and Spain. Patrick M. Forde's co-authors include Julie R. Brahmer, Jarushka Naidoo, Evan J. Lipson, David S. Ettinger, Kristen A. Marrone, Suzanne L. Topalian, Ronan J. Kelly, Leisha A. Emens, Janis M. Taube and Christine L. Hann and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Medicine and Nature Communications.

In The Last Decade

Patrick M. Forde

176 papers receiving 5.7k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non–Small Cell Lung Cancer

2020 320 citations Jiajia Zhang, Patrick M. Forde et al. profile →
Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors

2021 257 citations Giuseppe Curigliano, Hans Gelderblom et al. Clinical Cancer Research profile →
Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy

2023 153 citations Suzanne L. Topalian, Patrick M. Forde et al. profile →
Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges

2023 105 citations Patrick M. Forde, Solange Peters et al. profile →
Neoadjuvant Chemoimmunotherapy for NSCLC

2024 89 citations Patrick M. Forde, Tina Cascone et al. profile →
Clinical development of immuno-oncology therapeutics

2025 15 citations Jianxin Wang, Qi Shan et al. Cancer Letters profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Patrick M. Forde	4.0k	2.7k	1.1k	934	645	186	5.7k
Mary J. Fidler	5.2k 1.3×	3.7k 1.3×	1.1k 1.0×	803 0.9×	748 1.2×	115	6.4k
Kirsten B. Goldberg	2.7k 0.7×	1.3k 0.5×	712 0.6×	979 1.0×	711 1.1×	66	4.5k
Naoyuki Nogami	5.9k 1.5×	5.4k 2.0×	757 0.7×	1.4k 1.5×	969 1.5×	149	7.4k
Hidetoshi Hayashi	3.7k 0.9×	2.8k 1.0×	488 0.4×	1.4k 1.5×	705 1.1×	248	5.2k
Peter Langmuir	1.8k 0.5×	1.6k 0.6×	888 0.8×	1.3k 1.4×	507 0.8×	56	4.7k
Ranee Mehra	4.1k 1.0×	2.3k 0.8×	954 0.8×	1.5k 1.6×	746 1.2×	194	6.5k
Martin Sebastian	4.1k 1.0×	3.3k 1.2×	945 0.8×	1.7k 1.9×	930 1.4×	117	5.8k
Andrea Fülöp	7.9k 2.0×	5.3k 1.9×	1.8k 1.6×	898 1.0×	1.2k 1.8×	14	9.2k
Julia A. Beaver	2.7k 0.7×	1.5k 0.6×	519 0.5×	1.1k 1.2×	1.1k 1.7×	131	4.8k
Suman Rao	7.9k 2.0×	5.4k 2.0×	1.8k 1.6×	895 1.0×	1.2k 1.8×	21	9.3k

Countries citing papers authored by Patrick M. Forde

Since Specialization

Citations

This map shows the geographic impact of Patrick M. Forde's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick M. Forde with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick M. Forde more than expected).

Fields of papers citing papers by Patrick M. Forde

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick M. Forde. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick M. Forde. The network helps show where Patrick M. Forde may publish in the future.

Co-authorship network of co-authors of Patrick M. Forde

This figure shows the co-authorship network connecting the top 25 collaborators of Patrick M. Forde. A scholar is included among the top collaborators of Patrick M. Forde based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patrick M. Forde. Patrick M. Forde is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wang, Jianxin, et al.. (2025). Clinical development of immuno-oncology therapeutics. Cancer Letters. 617. 217616–217616. 15 indexed citations breakdown →

Rodgers, Kristen, James R. Eshleman, Peng Huang, et al.. (2025). PD-L1 pfeRNAs as blood-based predictors of treatment response of unresectable malignant pleural mesothelioma patients administered Durvalumab with cisplatin and pemetrexed as first-line therapy. Non-coding RNA Research. 12. 34–41.

Spicer, Jonathan, Nicolas Girard, Mariano Provencio, et al.. (2024). Neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with resectable NSCLC: 4-year update from CheckMate 816.. Journal of Clinical Oncology. 42(17_suppl). LBA8010–LBA8010. 25 indexed citations

Forde, Patrick M., Solange Peters, S. Meadows–Shropshire, et al.. (2024). PL02.08 Perioperative vs Neoadjuvant Nivolumab for Resectable NSCLC: Patient-Level Data Analysis of CheckMate 77T vs CheckMate 816. Journal of Thoracic Oncology. 19(10). S2–S2. 14 indexed citations

Rosner, Samuel, Joshua E. Reuss, Marianna Zahurak, et al.. (2023). Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non–Small Cell Lung Cancer. Clinical Cancer Research. 29(4). 705–710. 44 indexed citations

Awad, Mark M., Patrick M. Forde, Nicolas Girard, et al.. (2023). 1261O Neoadjuvant nivolumab (N) + ipilimumab (I) vs chemotherapy (C) in the phase III CheckMate 816 trial. Annals of Oncology. 34. S731–S731. 14 indexed citations

Forde, Patrick M., et al.. (2023). Neoadjuvant immune checkpoint inhibitor therapy in resectable non-small cell lung cancer. Lung Cancer. 183. 107314–107314. 9 indexed citations

Sanber, Khaled, Samuel Rosner, Patrick M. Forde, & Kristen A. Marrone. (2023). Neoadjuvant Immunotherapy for Non-Small Cell Lung Cancer. BioDrugs. 37(6). 775–791. 4 indexed citations

Anagnostou, Valsamo, et al.. (2022). Translating the evolving molecular landscape of tumors to biomarkers of response for cancer immunotherapy. Science Translational Medicine. 14(670). eabo3958–eabo3958. 29 indexed citations

10.

Curigliano, Giuseppe, Hans Gelderblom, Nicolas Mach, et al.. (2021). Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors. Clinical Cancer Research. 27(13). 3620–3629. 257 indexed citations breakdown →

11.

Prichett, Laura, Julie R. Brahmer, Patrick M. Forde, et al.. (2021). Association of severe lymphopenia and disease progression in unresectable locally advanced non-small cell lung cancer treated with definitive chemoradiation and immunotherapy. Lung Cancer. 154. 36–43. 38 indexed citations

12.

Chen, Xuguang, Khadija Sheikh, Erica C. Nakajima, et al.. (2021). Radiation Versus Immune Checkpoint Inhibitor Associated Pneumonitis: Distinct Radiologic Morphologies. The Oncologist. 26(10). e1822–e1832. 39 indexed citations

13.

Hazell, Sarah Z., Wei Fu, Peijin Han, et al.. (2020). Consolidative Radiotherapy in Oligometastatic Lung Cancer: Patient Selection With a Prediction Nomogram. Clinical Lung Cancer. 21(6). e622–e632. 8 indexed citations

14.

Fu, Wei, Chen Hu, Sarah Z. Hazell, et al.. (2020). Isolated progression of metastatic lung cancer: Clinical outcomes associated with definitive radiotherapy. Cancer. 126(20). 4572–4583. 11 indexed citations

15.

Stein, Julie E., Evan J. Lipson, Tricia R. Cottrell, et al.. (2019). Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade. Clinical Cancer Research. 26(3). 545–551. 92 indexed citations

16.

Danilova, Ludmila, Valsamo Anagnostou, Justina X. Caushi, et al.. (2018). The Mutation-Associated Neoantigen Functional Expansion of Specific T Cells (MANAFEST) Assay: A Sensitive Platform for Monitoring Antitumor Immunity. Cancer Immunology Research. 6(8). 888–899. 99 indexed citations

17.

Phallen, Jillian, Alessandro Leal, Brian Woodward, et al.. (2018). Early Noninvasive Detection of Response to Targeted Therapy in Non–Small Cell Lung Cancer. Cancer Research. 79(6). 1204–1213. 73 indexed citations

18.

Horn, Leora, Joshua Bauml, Patrick M. Forde, et al.. (2018). Real-world treatment patterns and survival of patients with BRAF V600-mutated metastatic non-small cell lung cancer. Lung Cancer. 128. 74–90. 12 indexed citations

19.

Trolliet, María R., Patrick M. Forde, Murray A. Rudd, & Joseph Loscalzo. (2000). Effect of Antioxidants on Salt-Induced Hypertension and Renal Dysfunction.. Hypertension. 36. 685–685. 1 indexed citations

20.

Forde, Patrick M., et al.. (1978). Pregnancy associated with uterine abnormality.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 71(5). 164–5. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact